WHO Pharmaceuticals Newsletter 1999, No. 01&02
(1999; 16 pages)
Table of Contents
Open this folder and view contentsRegulatory actions
Open this folder and view contentsDrug surveillance
Close this folderNew developments
View the documentAbacavir: approved for HIV-1 infection: USA
View the documentAcetylsalicylic acid: approved for use in cardiovascular and cerebrovascular conditions: USA
View the documentCelecoxib: approved for treatment of rheumatoid arthritis and osteoarthritis: USA
View the documentCilostazol: approved for treatment of stable intermittent claudication: USA
View the documentInterferon alfa-2b and ribavirin combination therapy: indications extended: previously untreated hepatitis C patients: USA
View the documentNew formulations
View the documentNewly approved products
View the documentMedical devices
View the documentCFC-free aerosol inhalers (MDIs): update: Malaysia
View the documentLaser for blood tests: approved for home use in diabetic patients: USA
Open this folder and view contentsGeneral information
Open this folder and view contentsMedication errors
Open this folder and view contentsVeterinary medicine
 

New formulations

budesonide

Budenofalk, Corticofalk: Dr Falk Pharma: Germany

New formulation: gastric acid-resistant pellets in capsule 3 mg

glucocorticosteroid

Indications: Acute mild to moderate Crohn’s disease.

desmopressin acetate

Noresis Nasenspray; Noresis Rhinyle, Noresis Rhinetten: Ferring: Germany

New formulations: nasal spray 500 micrograms/5mL; nose drops 250 micrograms/2.5mL; single dose pipettes 20 micrograms/0.2mL

synthetic vasopressin analogue

Indications: As an antidiuretic in diabetes insipidus; polyuria and polydipsia due to a temporary deficiency of antidiuretic hormone (ADH) after hypophysectomy, surgery of the pituitary gland or cranial/cerebral trauma; treatment of nocturnal enuresis in patients for whom other non-medicinal therapy was ineffective or as adjunctive therapy; nocturnal enuresis due to nocturnal ADH deficiency; as a diagnostic aid for the determination of levels of renal concentration or differential diagnosis of diabetes insipidus.

famciclovir

Famciclovir-SB, Famvir, Smithkline Beecham: Germany

New formulation: coated tablet 125 mg

antiviral agent

Indications: Acute treatment of Herpes genitalis (first occurrence), early treatment of recurrent H. genitalis, and long-term prophylactic treatment for suppression of symptoms of very severe and very frequent recurrences (more than 9 per year) of progressive forms of genital herpes.

pantoprazole

Pantoloc, Byk Gulden: Germany

New strength: enteric coated tablet 20 mg

cholinergic antisecretory agent

Indications: Symptomatic improvement and healing of mild to moderate reflux oesophagitis; longterm treatment and prophylaxis of recurrent reflux oesophagitis.

*zolmitriptan

Prevasmo; Zomig, Zeneca: Germany

New formulation: coated tablet 5 mg

serotonin receptor agonist

Indications: Acute treatment of headache due to migraine attacks with and without aura.

to previous section to next section
 

Last updated: May 3, 2013